Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

BUY
$3.34 - $4.29 $4,736 - $6,083
1,418 New
1,418 $5,000
Q1 2023

Jun 13, 2024

BUY
$3.95 - $5.63 $47,407 - $67,571
12,002 New
12,002 $49,000
Q4 2022

Feb 01, 2023

BUY
$3.02 - $5.37 $50,376 - $89,576
16,681 New
16,681 $87,000

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.75B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Bank Of Montreal Portfolio

Follow Bank Of Montreal and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.